72%, 11 données manquantes) La proportion de patients avec un OMS 3 était largement minoritaire, p.1 ,
Incidence and management of malignant digestive endocrine tumours in a well defined French population, Gut, vol.53, issue.4, pp.549-553, 2004. ,
DOI : 10.1136/gut.2003.026401
Epidemiologie des tumeurs neuroendocrines digestives : la situation en france, Hepato Gastro, vol.20, pp.160-166, 2013. ,
Thirteen-Month Registration of Patients with Gastroenteropancreatic Endocrine Tumours in France, Neuroendocrinology, vol.89, issue.2, pp.217-222, 2009. ,
DOI : 10.1159/000151562
Genetics of neuroendocrine and carcinoid tumours, Endocrine Related Cancer, vol.10, issue.4, pp.437-450, 2003. ,
DOI : 10.1677/erc.0.0100437
Gastropancreatic neuroendocrine tumours, Lancet Oncol, issue.9, pp.61-72, 2008. ,
The apud cell concept and its implications in pathology, Pathol Annu, issue.9, pp.27-41, 1974. ,
Revised classification of neuroendocrine tumours of the lung, pancreas and gut, Virchows Archiv, vol.425, issue.6, pp.547-560, 1995. ,
DOI : 10.1007/BF00199342
Tumeurs neuroendocrines du tube digestif et du pancr??as??: ce que le pathologiste doit savoir et doit faire en 2014, Annales de Pathologie, vol.34, issue.1, pp.40-50, 2014. ,
DOI : 10.1016/j.annpat.2014.01.003
THE CLASSIFICATION OF CARCINOID TUMOURS, The Lancet, vol.281, issue.7275, pp.238-239, 1963. ,
DOI : 10.1016/S0140-6736(63)90951-6
Who classification of tumours of the digestive system, International Agency for Research on Cancer (IARC), 2010. ,
Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas, The American Journal of Surgical Pathology, vol.38, issue.4, pp.437-447 ,
DOI : 10.1097/PAS.0000000000000169
Are G3 ENETS neuroendocrine neoplasms heterogeneous?, Endocrine Related Cancer, vol.20, issue.5, pp.649-657, 2013. ,
DOI : 10.1530/ERC-13-0027
Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses, Gut, vol.46, issue.2, pp.244-249, 2000. ,
DOI : 10.1136/gut.46.2.244
Histological typing of endocrine tumours. International Histological Classification of Tumours, pp.61-68, 2000. ,
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system, Virchows Archiv, vol.80, issue.Suppl 4, pp.395-401, 2006. ,
DOI : 10.1007/s00428-006-0250-1
TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system, Virchows Archiv, vol.80, issue.Suppl 4, pp.757-762, 2007. ,
DOI : 10.1007/s00428-007-0452-1
Tnm classification of malignant tumours, 2009. ,
DOI : 10.1002/0471463752
TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study, JNCI Journal of the National Cancer Institute, vol.104, issue.10, pp.764-777, 2012. ,
DOI : 10.1093/jnci/djs208
Prognostic Validity of the American Joint Committee on Cancer Staging Classification for Midgut Neuroendocrine Tumors, Journal of Clinical Oncology, vol.31, issue.4, pp.420-425, 2013. ,
DOI : 10.1200/JCO.2012.44.5924
ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors, Neuroendocrinology, vol.95, issue.2, pp.120-134, 2012. ,
DOI : 10.1159/000335587
Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor, Surgery, vol.150, issue.1, pp.75-82, 2011. ,
DOI : 10.1016/j.surg.2011.02.022
GEP-NETS UPDATE: A review on surgery of gastro-entero-pancreatic neuroendocrine tumors, European Journal of Endocrinology, vol.171, issue.4, pp.153-162, 2014. ,
DOI : 10.1530/EJE-14-0173
Treatment of carcinoid syndrome : a prospective crossover evaluation of lanreotide versus octrotide in terms of efficacy, patient acceptability, and tolerance, Cancer, vol.88, pp.770-776, 2000. ,
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group, Journal of Clinical Oncology, vol.27, issue.28 ,
DOI : 10.1200/JCO.2009.22.8510
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.371, issue.3, pp.224-233, 2014. ,
DOI : 10.1056/NEJMoa1316158
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms, Cancer, vol.109, issue.2, pp.227-232, 1991. ,
DOI : 10.1002/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study, Annals of Oncology, vol.24, issue.1, pp.152-160, 2013. ,
DOI : 10.1093/annonc/mds276
New treatment options with cytotoxic agents in neuroendocrine tumours, Targeted Oncology, vol.117, issue.16S, pp.169-72, 2012. ,
DOI : 10.1007/s11523-012-0228-7
O6-methylguanine dna methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors, Clin Cancer Res, vol.15, pp.338-345, 2009. ,
Everolimus for Advanced Pancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.364, issue.6, pp.514-523, 2011. ,
DOI : 10.1056/NEJMoa1009290
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.364, issue.6, pp.501-513, 2011. ,
DOI : 10.1056/NEJMoa1003825
Hepatic Arterial Embolization versus Chemoembolization in the Treatment of Liver Metastases from Well-Differentiated Midgut Endocrine Tumors: A Prospective Randomized Study, Neuroendocrinology, vol.96, issue.4, pp.294-300, 2012. ,
DOI : 10.1159/000336941
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary, Neuroendocrinology, vol.95, issue.2, pp.157-176, 2012. ,
DOI : 10.1159/000335597
Tumeurs neuroendocrines digestives de grade 3 bien differenciees : mythe ou realite ? etude pronet, 2013. ,
Clinical characteristics of the 5 160 patients included in the french database of the french endocrine tumor group (gte), ENETS Lisbon, 2011. ,
Epidemiologie des tumeurs endocrines digestives. Hepato- Gastro, pp.5-8, 2009. ,
Survival From Malignant Digestive Endocrine Tumors in England and Wales: A Population-Based Study, Gastroenterology, vol.132, issue.3, pp.899-904, 2007. ,
DOI : 10.1053/j.gastro.2007.01.006
Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters, Endocrine Related Cancer, vol.17, issue.4, pp.909-918, 2010. ,
DOI : 10.1677/ERC-10-0152
One Hundred Years After ???Carcinoid???: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States, Journal of Clinical Oncology, vol.26, issue.18, pp.3063-3072, 2008. ,
DOI : 10.1200/JCO.2007.15.4377
Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: Epidemiological changes in Germany, World Journal of Gastroenterology, vol.19, issue.47, pp.9012-9019, 2013. ,
DOI : 10.3748/wjg.v19.i47.9012
European disparities in malignant digestive endocrine tumours survival, International Journal of Cancer, vol.14, pp.2928-2934, 2010. ,
DOI : 10.1002/ijc.24698
Tnm classification of malignant tumors, fifth edition. Union Internationale Contre le Cancer and the American Joint Committee on Cancer, pp.1803-1804, 1997. ,
Significance of the preoperative neutrophil-to-lymphocyte ratio in the prognosis of patients with gastric cancer, World Journal of Gastroenterology, vol.21, issue.20, pp.6280-6286, 2015. ,
DOI : 10.3748/wjg.v21.i20.6280
Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma, World Journal of Surgical Oncology, vol.12, issue.1, p.58, 2014. ,
DOI : 10.1007/s00268-011-1130-7
Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature, Endocrine Related Cancer, vol.21, issue.3, pp.153-163, 2014. ,
DOI : 10.1530/ERC-13-0125
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE), Annals of Oncology, vol.21, issue.9, pp.1794-1803, 2010. ,
DOI : 10.1093/annonc/mdq022
Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (???10%) Well-Differentiated Endocrine Carcinoma Staging, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.3, pp.665-671, 2011. ,
DOI : 10.1210/jc.2010-2022
Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors, Journal of Nuclear Medicine, vol.50, issue.6, pp.858-864, 2009. ,
DOI : 10.2967/jnumed.108.057505